GET DAILY SIGNALSMilestone Pharmaceuticals (MIST): Transitioning to Commercial Stage in Cardiovascular Medicine
Key Takeaways
- MIST is the Nasdaq ticker for Milestone Pharmaceuticals Inc., a Canadian-headquartered biopharmaceutical company focused on cardiovascular medicines.
- The company's lead product is CARDAMYST (etripamil) nasal spray, approved by the U.S. Food and Drug Administration (FDA) in December 2025 for treating paroxysmal supraventricular tachycardia (PSVT) in adults.
- Milestone operates a research-and-commercialization business model, relying on contract manufacturers rather than owning production facilities.
- The company is also developing etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR), with a Phase 3 program underway.
- As an early commercial-stage biotech, Milestone has historically generated losses and remains dependent on additional capital and successful product uptake.
Company Overview
Milestone Pharmaceuticals Inc. is an emerging commercial-stage biopharmaceutical company dedicated to developing and marketing innovative cardiovascular treatments. Investors follow MIST because the company recently secured U.S. regulatory approval for its first commercial product and is transitioning from a research-stage organization into a revenue-generating business. Its company overview centers on a single molecule, etripamil, which the company designed as a rapid-onset, self-administered nasal spray for heart-rhythm conditions.
Corporate Background and Product Details
Milestone Pharmaceuticals was incorporated under the laws of Québec, Canada, in 2003, and was founded by Philippe Douville and Philippe Lamarre. The company is headquartered in Montréal, Québec, with an additional U.S. office in Charlotte, North Carolina. Its common shares began trading on the Nasdaq Global Select Market on May 9, 2019, under the symbol MIST.
The company's core product is CARDAMYST, the brand name for etripamil nasal spray. Etripamil is a novel, potent, short-acting calcium channel blocker — a class of medicines that act on the heart's electrical conduction system to slow a rapid heartbeat. CARDAMYST was approved by the FDA on December 12, 2025, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm in adults. PSVT is a recurring heart-rhythm disorder characterized by sudden, rapid heartbeats that can cause palpitations, dizziness, chest discomfort, and anxiety. CARDAMYST is positioned as the first FDA-approved therapy that patients can self-administer outside a medical setting, reducing reliance on emergency-department visits.
Milestone's business model combines drug development with commercialization. Because the company does not own manufacturing facilities, it contracts with third-party manufacturing organizations for its active ingredient, nasal-spray device, and finished product, and uses a third-party logistics provider for distribution. After FDA approval, the company deployed a specialized sales force of roughly 60 representatives targeting cardiologists, electrophysiologists, and other healthcare providers. Beyond the United States, Milestone has a license and collaboration agreement with Corxel Pharmaceuticals covering greater China, and it submitted a marketing authorization application to the European Medicines Agency (EMA) under the trade name TACHYMIST.
Milestone's primary revenue source is currently limited. The company recorded modest milestone-based license revenue and only began generating product sales following CARDAMYST's commercial launch in early 2026. Its financial profile reflects its development stage: Milestone reported a net loss of $63.1 million for 2025 and an accumulated deficit of $430.6 million, while holding about $106 million in cash, cash equivalents, and short-term investments at year-end 2025.
Investment Appeal of MIST
Investors follow MIST largely because of the novelty of its product and the size of its target market. CARDAMYST is the first FDA-approved self-administered treatment for PSVT in roughly three decades, giving the company a differentiated market position with no direct branded competitor in its core indication. The company estimates that PSVT affects more than two million Americans, and it is pursuing additional indications for etripamil — most notably atrial fibrillation with rapid ventricular rate (AFib-RVR) — which could broaden its addressable market considerably.
Several strategic factors underpin the company's long-term growth story. Its intellectual-property portfolio includes patents extending into the 2030s and 2040s, and the company retains U.S. commercialization rights while partnering for certain international territories. The shift toward patient-administered, out-of-hospital care also aligns CARDAMYST with payer interest in reducing costly emergency-room utilization. These attributes, combined with a cash position intended to fund operations into the late 2020s, make Milestone a closely watched name among investors focused on commercial-stage biotechnology. When comparing peers in the sector, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Potential Risks to Consider
Milestone carries risks common to small biotechnology and newly commercialized pharmaceutical companies. The company has only one approved product, so its near-term prospects depend heavily on CARDAMYST's commercial success, including physician adoption, payer coverage, and reimbursement. Market acceptance is not guaranteed, and the company anticipates continued operating losses until product revenue scales sufficiently.
Additional risks include reliance on third-party manufacturers and a single-source nasal-spray device supplier, intense competition in cardiovascular medicine, regulatory and pricing pressures in the U.S. and abroad, and the inherent uncertainty of clinical development for its pipeline indications such as AFib-RVR. As a smaller reporting company with a limited operating history as a commercial business, Milestone may also require additional financing, which could dilute existing shareholders.
Using AI Tools for Further Analysis
In my own research process, Tickeron's AI Screener has proven useful for identifying patterns and filtering opportunities across biotech names. It allows users to apply technical indicators, fundamentals, and customizable criteria to quickly narrow down ideas that align with specific strategies, which can help streamline comparisons when evaluating companies like MIST alongside sector peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MIST's Indicator enters downward trend
The Aroon Indicator for MIST entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 212 similar instances where the Aroon Indicator formed such a pattern. In 189 of the 212 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MIST's RSI Indicator exited the oversold zone, 27 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 57 cases where MIST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MIST as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 27, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MIST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement